These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 2968761

  • 1. Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Jacobi GH, Wenderoth UK, Ehrenthal W, von Wallenberg H, Spindler HW, Hohenfellner R.
    Am J Clin Oncol; 1988; 11 Suppl 1():S36-43. PubMed ID: 2968761
    [Abstract] [Full Text] [Related]

  • 2. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK, Spindler HW, Ehrenthal W, von Wallenberg H, Happ J, Jacobi GH.
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract] [Full Text] [Related]

  • 3. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK, Jacobi GH.
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [Abstract] [Full Text] [Related]

  • 4. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V, al-Abadi H, Nagel R.
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [Abstract] [Full Text] [Related]

  • 5. A long term follow-up of patients with advanced prostatic cancer treated with buserelin.
    Waxman JH, Hendry WF, Whitfield HN, Oliver RT.
    Prog Clin Biol Res; 1985; 185A():271-7. PubMed ID: 3929266
    [Abstract] [Full Text] [Related]

  • 6. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 7. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T, Kishimoto T, Shimazaki J, Yoshida O, Isurugi K.
    Hinyokika Kiyo; 1988 Jul 01; 34(7):1309-19. PubMed ID: 3140622
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
    Schlegel PN, Histrelin Study Group.
    J Urol; 2006 Apr 01; 175(4):1353-8. PubMed ID: 16515997
    [Abstract] [Full Text] [Related]

  • 11. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR, Denis L, Mahler C, Walker K, Stitch R, Lunglmayr G.
    Eur J Surg Oncol; 1985 Jun 01; 11(2):159-65. PubMed ID: 3159598
    [Abstract] [Full Text] [Related]

  • 12. Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
    Matzkin H, Greenstein A, Kaver I, Braf Z.
    Isr J Med Sci; 1989 Jul 01; 25(7):388-92. PubMed ID: 2474522
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
    Wenderoth UK, Jacobi GH.
    Ann Urol (Paris); 1986 Jul 01; 20(2):95-7. PubMed ID: 3087269
    [Abstract] [Full Text] [Related]

  • 14. Management of metastatic prostatic cancer.
    Paulson DF.
    Urology; 1985 Feb 01; 25(2 Suppl):49-52. PubMed ID: 3918376
    [Abstract] [Full Text] [Related]

  • 15. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
    Pfitzenmaier J, Altwein JE.
    Aktuelle Urol; 2009 Mar 01; 40(2):100-8. PubMed ID: 19253209
    [Abstract] [Full Text] [Related]

  • 16. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J.
    Am J Clin Oncol; 1988 Mar 01; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
    Migliari R, Scarpa RM, Campus G, De Lisa A, Zucca I, D'Atri M, Serra A, Usai E.
    Arch Ital Urol Nefrol Androl; 1991 Mar 01; 63(1):147-53. PubMed ID: 1830407
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Mar 01; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 19. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B, Spitz IM, Lindenberg T, Algur N, Zer T, Kuzma P, Young AJ, Catane R, Farkas A.
    J Urol; 2000 Mar 01; 163(3):838-44. PubMed ID: 10687989
    [Abstract] [Full Text] [Related]

  • 20. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy.
    De Sy WA, De Wilde P, De Meyer JM, Casselman J, Desmet R, Renders G, Schelfhout W.
    Acta Urol Belg; 1988 Mar 01; 56(4):581-8. PubMed ID: 2974680
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.